Appropriate Use of Inpatient Erythropoiesis Stimulating Agents

<i>Background</i>: Anemia is a significant global public health issue, and is associated with lethargy, weakness, tiredness, and shortness of breath. Erythropoiesis stimulating agents (ESAs) are recombinant/synthetic erythropoietin and can increase hemoglobin (Hb) levels. There are increased risks of cardiovascular events and death associated with the use of ESAs when raising Hb levels above 12 g/dL. <i>Methods:</i> The objective was to assure safety and appropriate use of ESA. We performed a baseline assessment via a retrospective chart review, including patients who recently received an inpatient dose of an ESA within Mount Sinai Hospital (MSH) from November 1, 2015 (after MSH ESA guideline revision) to August 1, 2023. All adult patients who received an ESA (originator or biosimilar products) during hospitalization were included. Data collection was in reverse chronology, and the most recent dose administered to each unique patient was collected. <i>Results</i>: If an ESA dose was dispensed when the Hb was less than the upper limit of the target Hb for the specific indication, this was considered appropriate use. Based on data from June 15 to August 1, 2023 (~47 days of inpatient utilization), for the primary outcome, 169 out of 171 doses (98.8%) met the predefined criteria for appropriateness. One dose was dispensed when the Hb was 11.1 g/dL to a patient on renal replacement therapy, and one dose was dispensed when the Hb was 13.8 g/dL to a surgical patient who refused blood transfusions. Among secondary outcomes of interest, there was a difference in blood transfusions administered in critical versus non-critical care settings. <i>Conclusion</i>: Inpatient use of ESA at MSH was appropriate when looking at Hb targets. There are currently no formal order sets, service-line restrictions, or additional chairperson approvals needed at MSH. Despite this, there remained significant adherence to prevailing Hb targets, reflecting provider and pharmacy teams' knowledge and awareness of contemporary best practices.

Authors

Institutions

Publication Details

Journal
INNOVATIONS in pharmacy
Published
2024-11-26
DOI
https://doi.org/10.24926/iip.v15i4.6284
Primary Topic
Erythropoietin and Anemia Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Appropriate Use of Inpatient Erythropoiesis Stimulating Agents

Mohammad Rattu, Timothy Nguyen, Chenghao Cui
INNOVATIONS in pharmacy
Erythropoietin and Anemia Treatment
article

Appropriate Use of Inpatient Erythropoiesis Stimulating Agents

Mohammad Rattu, Timothy Nguyen, Chenghao Cui
article en

Abstract

<i>Background</i>: Anemia is a significant global public health issue, and is associated with lethargy, weakness, tiredness, and shortness of breath. Erythropoiesis stimulating agents (ESAs) are recombinant/synthetic erythropoietin and can increase hemoglobin (Hb) levels. There are increased risks of cardiovascular events and death associated with the use of ESAs when raising Hb levels above 12 g/dL. <i>Methods:</i> The objective was to assure safety and appropriate use of ESA. We performed a baseline assessment via a retrospective chart review, including patients who recently received an inpatient dose of an ESA within Mount Sinai Hospital (MSH) from November 1, 2015 (after MSH ESA guideline revision) to August 1, 2023. All adult patients who received an ESA (originator or biosimilar products) during hospitalization were included. Data collection was in reverse chronology, and the most recent dose administered to each unique patient was collected. <i>Results</i>: If an ESA dose was dispensed when the Hb was less than the upper limit of the target Hb for the specific indication, this was considered appropriate use. Based on data from June 15 to August 1, 2023 (~47 days of inpatient utilization), for the primary outcome, 169 out of 171 doses (98.8%) met the predefined criteria for appropriateness. One dose was dispensed when the Hb was 11.1 g/dL to a patient on renal replacement therapy, and one dose was dispensed when the Hb was 13.8 g/dL to a surgical patient who refused blood transfusions. Among secondary outcomes of interest, there was a difference in blood transfusions administered in critical versus non-critical care settings. <i>Conclusion</i>: Inpatient use of ESA at MSH was appropriate when looking at Hb targets. There are currently no formal order sets, service-line restrictions, or additional chairperson approvals needed at MSH. Despite this, there remained significant adherence to prevailing Hb targets, reflecting provider and pharmacy teams' knowledge and awareness of contemporary best practices.

INNOVATIONS in pharmacyVol. 15(4)
Long Island University (US), Mount Sinai Hospital (US)
Good health and well-being
Openalex Percentile: Top 64%
Erythropoietin and Anemia Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.